NASDAQ$IMNN
Celsion Corp · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
IMUNON reported financial results for the third quarter of 2022 and provided a business update.
IMUNON reported a net loss of $6.1 million, or $0.87 per share, for the third quarter of 2022, compared to a net loss of $5.4 million, or $0.94 per share, for the third quarter of 2021. The company's operating expenses were $6.3 million for the third quarter of 2022, an increase of $1.1 million from the comparable prior-year period. The company ended the quarter with $43.4 million in cash, investments, restricted cash and accrued interest receivable and believes it has sufficient capital resources to fund its operations into 2025.
- IMUNON is making excellent progress with innovative development modalities in infectious diseases and immuno-oncology.
- PLACCINE modality continues to advance with very promising data from a non-human primate proof-of-concept study comparing vaccine with commercial mRNA vaccines.
- Enrollment in the 110-patient OVATION 2 Study of GEN-1 in advanced ovarian cancer was completed during the third quarter.
- Decision to raise additional capital earlier this year to strengthen balance sheet and extend operating roadway into 2025 was well timed.
Headline financials
Revenue & EPS history
Celsion · Revenue · Quarterly
$125K
Forward guidance
IMUNON expects to report several value-creating developments during this period and believes it has sufficient capital resources to fund its operations into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+0.2%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+3.5%
Avg return
30 days after
32%
12 / 38 earnings
Positive
+28.7%
Q3 2019
Best reaction
-12.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.1% | -8.8% | — | |
| Q2 2025 | -4.8% | -10.3% | -28.5% | |
| Q1 2025 | +2.5% | -40.0% | +107.5% | |
| Q4 2024 | +1.2% | +6.3% | +36.2% | |
| Q3 2024 | -12.8% | -17.0% | -10.6% | |
| Q2 2024 | -0.9% | +4.6% | +1.8% | |
| Q1 2024 | +7.2% | +1.4% | -11.6% | |
| Q4 2023 | +17.1% | +25.0% | +2.9% | |
| Q3 2023 | -4.0% | -3.0% | -9.1% | |
| Q2 2023 | -3.2% | -5.6% | -10.4% | |
| Q1 2023 | -5.2% | -6.7% | +3.7% | |
| Q4 2022 | -2.3% | -6.2% | +0.8% | |
| Q3 2022 | -3.9% | -4.6% | -11.1% | |
| Q2 2022 | -1.6% | -11.6% | -19.8% | |
| Q1 2022 | +0.4% | -7.5% | -23.5% | |
| Q4 2021 | -4.5% | +17.4% | -45.3% | |
| Q3 2021 | +1.2% | -10.7% | -22.6% | |
| Q2 2021 | -1.9% | -8.4% | +0.0% | |
| Q1 2021 | +4.0% | +12.1% | +54.5% | |
| Q4 2020 | -1.3% | -22.9% | -53.3% | |
| Q3 2020 | -1.9% | -3.7% | +24.1% | |
| Q2 2020 | +0.0% | -1.8% | -28.4% | |
| Q1 2020 | -1.5% | +26.5% | +125.0% | |
| Q4 2019 | +9.0% | -3.4% | +31.5% | |
| Q3 2019 | +28.7% | +34.3% | +50.0% | |
| Q2 2019 | +0.0% | +7.1% | +3.0% | |
| Q1 2019 | +6.1% | -4.2% | -15.4% | |
| Q4 2018 | -2.5% | +19.9% | +6.5% | |
| Q3 2018 | -4.2% | -12.6% | -8.8% | |
| Q2 2018 | -9.4% | -8.7% | +2.2% | |
| Q1 2018 | -1.6% | +1.2% | +0.0% | |
| Q4 2017 | -4.3% | -11.5% | -12.6% | |
| Q3 2017 | -5.2% | -5.7% | +32.1% | |
| Q2 2017 | -1.4% | -9.5% | -5.4% | |
| Q1 2017 | +0.0% | -8.3% | -14.0% | |
| Q4 2016 | +3.4% | -3.4% | +3.4% | |
| Q3 2016 | +0.0% | -10.9% | -27.2% | |
| Q2 2016 | +4.2% | +10.0% | +3.3% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro